- Home
- WTRG vs ABVX Comparison
WTRG vs ABVX Comparison
Compare WTRG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WTRG | ABVX |
|---|---|---|
| Founded | 1901 | 2013 |
| Country | United States | France |
| Employees | 1615 | 67 |
| Industry | Water Supply | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 9.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | WTRG | ABVX |
|---|---|---|
| Price | $38.08 | $118.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $43.50 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 1.9M | 756.8K |
| Earning Date | 05-07-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $2,474,615,000.00 | N/A |
| Revenue This Year | $5.07 | $52.14 |
| Revenue Next Year | $7.31 | $4,132.27 |
| P/E Ratio | $17.40 | ★ N/A |
| Revenue Growth | ★ 18.62 | N/A |
| 52 Week Low | $36.32 | $5.59 |
| 52 Week High | $42.37 | $148.83 |
Technical Indicators
Market Signals| Indicator | WTRG | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 52.63 |
| Support Level | $37.29 | $107.55 |
| Resistance Level | $40.01 | $129.84 |
| Average True Range (ATR) | 0.99 | 5.16 |
| MACD | -0.13 | -0.22 |
| Stochastic Oscillator | 15.91 | 57.93 |
Price Performance
Historical ComparisonAbout WTRG Essential Utilities Inc.
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.